A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and pharmacoeconomics of treatment with
subcutaneous (SC) epoetin beta (NeoRecormon) in participants with hematologic malignancies or
solid tumors. The anticipated time on study treatment is 20 weeks, and the target sample size
is 60 individuals.